$ACAD
ACADIA PHARMACEUTICALS INC

2015 Q4 Form 10-Q Financial Statement

#000119312515368368 Filed on November 05, 2015

View on sec.gov

Income Statement

Concept 2015 Q4 2015 Q3 2014 Q3
Revenue $17.00K $39.00K $15.00K
YoY Change -63.83% 160.0% -93.75%
Cost Of Revenue $2.500M
YoY Change
Gross Profit -$2.500M
YoY Change
Gross Profit Margin -14705.88%
Selling, General & Admin $22.60M $20.30M $8.100M
YoY Change 117.31% 150.62% 113.16%
% of Gross Profit
Research & Development $20.50M $18.73M $16.95M
YoY Change 12.64% 10.48% 133.69%
% of Gross Profit
Depreciation & Amortization $130.0K $120.0K $60.00K
YoY Change 116.67% 100.0% 50.0%
% of Gross Profit
Operating Expenses $43.10M $39.04M $25.01M
YoY Change 50.7% 56.09% 126.31%
Operating Profit -$45.60M -$39.00M -$24.99M
YoY Change 56.03% 131.19%
Interest Expense $100.0K $92.00K $208.0K
YoY Change -50.0% -55.77% 79.31%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income -$45.50M -$38.90M -$24.80M
YoY Change 60.21% 56.85% 131.78%
Income Tax $300.0K
% Of Pretax Income
Net Earnings -$45.78M -$38.91M -$24.79M
YoY Change 61.4% 56.97% 131.75%
Net Earnings / Revenue -269317.65% -99758.97% -165240.0%
Basic Earnings Per Share
Diluted Earnings Per Share -$452.6K -$385.9K -$249.2K
COMMON SHARES
Basic Shares Outstanding 100.9M shares 100.7M shares 99.44M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2015 Q4 2015 Q3 2014 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $215.1M $240.7M $337.8M
YoY Change -33.29% -28.75% 72.19%
Cash & Equivalents $102.1M $70.80M $36.37M
Short-Term Investments $113.0M $169.9M $301.4M
Other Short-Term Assets $2.200M $2.000M $2.100M
YoY Change 83.33% -4.76% -16.0%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $219.0M $242.8M $341.1M
YoY Change -32.54% -28.8% 71.67%
LONG-TERM ASSETS
Property, Plant & Equipment $2.203M $2.068M $520.0K
YoY Change 298.37% 297.69% 6.12%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $329.0K $405.0K $178.0K
YoY Change 14.63% 127.53% 48.33%
Total Long-Term Assets $2.907M $2.473M $698.0K
YoY Change 246.07% 254.3% 14.43%
TOTAL ASSETS
Total Short-Term Assets $219.0M $242.8M $341.1M
Total Long-Term Assets $2.907M $2.473M $698.0K
Total Assets $221.9M $245.3M $341.8M
YoY Change -31.82% -28.22% 71.49%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.672M $2.204M $1.110M
YoY Change -17.06% 98.56% -0.89%
Accrued Expenses $20.23M $15.53M $10.13M
YoY Change 46.4% 53.35% 51.84%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $21.90M $17.74M $11.25M
YoY Change 38.32% 57.6% 42.99%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $200.0K $200.0K $0.00
YoY Change 100.0% -100.0%
Total Long-Term Liabilities $232.0K $239.0K $21.00K
YoY Change 71.85% 1038.1% 950.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $21.90M $17.74M $11.25M
Total Long-Term Liabilities $232.0K $239.0K $21.00K
Total Liabilities $22.13M $17.97M $11.27M
YoY Change 38.61% 59.43% 43.22%
SHAREHOLDERS EQUITY
Retained Earnings -$662.6M -$616.8M -$469.8M
YoY Change 33.01% 31.3% 19.35%
Common Stock $10.00K $10.00K $10.00K
YoY Change 0.0% 0.0% 11.11%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $199.8M $227.3M $330.5M
YoY Change
Total Liabilities & Shareholders Equity $221.9M $245.3M $341.8M
YoY Change -31.82% -28.22% 71.49%

Cashflow Statement

Concept 2015 Q4 2015 Q3 2014 Q3
OPERATING ACTIVITIES
Net Income -$45.78M -$38.91M -$24.79M
YoY Change 61.4% 56.97% 131.75%
Depreciation, Depletion And Amortization $130.0K $120.0K $60.00K
YoY Change 116.67% 100.0% 50.0%
Cash From Operating Activities -$34.73M -$31.85M -$17.48M
YoY Change 95.11% 82.21% 84.58%
INVESTING ACTIVITIES
Capital Expenditures -$290.0K -$190.0K -$80.00K
YoY Change 222.22% 137.5% -81.4%
Acquisitions
YoY Change
Other Investing Activities $57.02M $8.490M $38.96M
YoY Change 40.55% -78.21% -1206.82%
Cash From Investing Activities $56.72M $8.310M $38.87M
YoY Change 40.12% -78.62% -1084.05%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 9.330M 1.130M 1.280M
YoY Change 232.03% -11.72% 31.96%
NET CHANGE
Cash From Operating Activities -34.73M -31.85M -17.48M
Cash From Investing Activities 56.72M 8.310M 38.87M
Cash From Financing Activities 9.330M 1.130M 1.280M
Net Change In Cash 31.32M -22.41M 22.67M
YoY Change 22.87% -198.85% -282.09%
FREE CASH FLOW
Cash From Operating Activities -$34.73M -$31.85M -$17.48M
Capital Expenditures -$290.0K -$190.0K -$80.00K
Free Cash Flow -$34.44M -$31.66M -$17.40M
YoY Change 94.47% 81.95% 92.48%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2015Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
225000000 shares
CY2014Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
36369000
CY2015Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2015Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
225000000 shares
CY2015Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
100896200 shares
CY2015Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2015Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2015Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
100896200 shares
CY2015Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2015Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2015Q3 us-gaap Liabilities Current
LiabilitiesCurrent
17735000
CY2015Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
844093000
CY2015Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
4984000
CY2015Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
15531000
CY2015Q3 us-gaap Liabilities
Liabilities
17974000
CY2015Q3 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
239000
CY2015Q3 us-gaap Common Stock Value
CommonStockValue
10000
CY2015Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
45000
CY2015Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2015Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
3364000
CY2015Q3 us-gaap Preferred Stock Value
PreferredStockValue
CY2015Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
1306000
CY2015Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-616802000
CY2015Q3 us-gaap Stockholders Equity
StockholdersEquity
227346000
CY2015Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
245320000
CY2015Q3 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
36000
CY2015Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
2204000
CY2015Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2068000
CY2015Q3 us-gaap Assets Current
AssetsCurrent
242847000
CY2015Q3 us-gaap Investments Fair Value Disclosure
InvestmentsFairValueDisclosure
240215000
CY2015Q3 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
96900000
CY2015Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
70799000
CY2015Q3 us-gaap Assets
Assets
245320000
CY2015Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1950000
CY2015Q3 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
169856000
CY2015Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
405000
CY2015Q3 us-gaap Interest Receivable Current
InterestReceivableCurrent
206000
CY2015Q3 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
169892000
CY2015Q3 acad Accrued Clinical Development Services
AccruedClinicalDevelopmentServices
5877000
CY2015Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
100911625 shares
CY2013Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
11707000
CY2014Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2014Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000 shares
CY2014Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
100047331 shares
CY2014Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2014Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2014Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
100047331 shares
CY2014Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2014Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2014Q4 us-gaap Liabilities Current
LiabilitiesCurrent
15834000
CY2014Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
807631000
CY2014Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
4167000
CY2014Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
13818000
CY2014Q4 us-gaap Liabilities
Liabilities
15969000
CY2014Q4 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
135000
CY2014Q4 us-gaap Common Stock Value
CommonStockValue
10000
CY2014Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-9000
CY2014Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2014Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
1497000
CY2014Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2014Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
340000
CY2014Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-498143000
CY2014Q4 us-gaap Stockholders Equity
StockholdersEquity
309489000
CY2014Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
325458000
CY2014Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
32000
CY2014Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
2016000
CY2014Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
553000
CY2014Q4 us-gaap Assets Current
AssetsCurrent
324618000
CY2014Q4 us-gaap Investments Fair Value Disclosure
InvestmentsFairValueDisclosure
322055000
CY2014Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
47000
CY2014Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
61854000
CY2014Q4 us-gaap Assets
Assets
325458000
CY2014Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1168000
CY2014Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
260647000
CY2014Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
287000
CY2014Q4 us-gaap Interest Receivable Current
InterestReceivableCurrent
964000
CY2014Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
260632000
CY2014Q4 acad Accrued Clinical Development Services
AccruedClinicalDevelopmentServices
7814000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
9699000 shares
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-48633000
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.66
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
97210000 shares
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-1000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-64080000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
86000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-345000
us-gaap Operating Income Loss
OperatingIncomeLoss
-64676000
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
567000
us-gaap Revenues
Revenues
72000
us-gaap Increase Decrease In Accounts Receivable And Other Operating Assets
IncreaseDecreaseInAccountsReceivableAndOtherOperatingAssets
389000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
307000
us-gaap Net Income Loss
NetIncomeLoss
-64109000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
29000
us-gaap Payments To Acquire Available For Sale Securities
PaymentsToAcquireAvailableForSaleSecurities
307211000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
201044000
us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
179548000
us-gaap Operating Expenses
OperatingExpenses
64748000
us-gaap Depreciation
Depreciation
145000
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
201044000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
22328000
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-40000
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
24662000
us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
13000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
738000
us-gaap Share Based Compensation
ShareBasedCompensation
11394000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
3576000
us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-127749000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
42420000
dei Document Type
DocumentType
10-Q
dei Trading Symbol
TradingSymbol
ACAD
dei Entity Central Index Key
EntityCentralIndexKey
0001070494
dei Document Period End Date
DocumentPeriodEndDate
2015-09-30
dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
11604000 shares
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P3Y
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-87073000
us-gaap Description Of New Accounting Pronouncements Not Yet Adopted
DescriptionOfNewAccountingPronouncementsNotYetAdopted
<div> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"> <b>9. Recent Accounting Pronouncements</b></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"> In April 2015, the Financial Accounting Standards Board (&#x201C;FASB&#x201D;) issued authoritative guidance related to accounting for fees paid in a cloud computing arrangement. This accounting update provides guidance to customers about whether a cloud computing arrangement includes a software license. If a cloud computing arrangement includes a software license, then the customer should account for the software license element of the arrangement consistent with the acquisition of other software licenses. If a cloud computing arrangement does not include a software license, the customer should account for the arrangement as a service contract. This guidance is effective for annual reporting periods beginning after December&#xA0;15, 2015 and early adoption is permitted. The Company adopted this guidance in the first quarter of fiscal 2015 with no significant impact to its consolidated financial statements.</p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"> In May 2014, the FASB issued authoritative accounting guidance related to revenue from contracts with customers. This guidance is a comprehensive new revenue recognition model that requires a company to recognize revenue to depict the transfer of goods or services to a customer at an amount that reflects the consideration it expects to receive in exchange for those goods or services. The original guidance was effective for annual reporting periods beginning after December&#xA0;15, 2016. However, in July 2015, the FASB agreed to delay the effective date by one year, with early adoption permitted, but not before the original effective date of the standard. In accordance with the agreed upon delay, the Company will adopt this guidance on January&#xA0;1, 2018. Companies may use either a full retrospective or a modified retrospective approach to adopt this guidance. The Company is evaluating which transition approach to use and its impact, if any, on its consolidated financial statements.</p> </div>
dei Amendment Flag
AmendmentFlag
false
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.18
dei Entity Registrant Name
EntityRegistrantName
ACADIA PHARMACEUTICALS INC
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
100436000 shares
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
144000
us-gaap Share Based Compensation
ShareBasedCompensation
31292000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
1571000
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2015
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
118000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-118605000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1848000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
1902000
us-gaap Operating Income Loss
OperatingIncomeLoss
-119047000
us-gaap Revenues
Revenues
44000
us-gaap Increase Decrease In Accounts Receivable And Other Operating Assets
IncreaseDecreaseInAccountsReceivableAndOtherOperatingAssets
-758000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
782000
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
388000
us-gaap Net Income Loss
NetIncomeLoss
-118659000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
51000
us-gaap Payments To Acquire Available For Sale Securities
PaymentsToAcquireAvailableForSaleSecurities
215926000
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
3000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
5170000
us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
308619000
us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents
EffectOfExchangeRateOnCashAndCashEquivalents
3000
us-gaap Operating Expenses
OperatingExpenses
119091000
us-gaap Depreciation
Depreciation
519000
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
5170000
us-gaap Noncash Or Part Noncash Acquisition Fixed Assets Acquired1
NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1
186000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
65688000
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
8945000
us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
104000
us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
90845000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
53403000
CY2014Q1 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
7360000 shares
CY2014Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
196800000
CY2014Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
9753000 shares
CY2014Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.25
CY2014Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
99497000 shares
CY2014Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-24803000
CY2014Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-24994000
CY2014Q3 us-gaap Revenues
Revenues
15000
CY2014Q3 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
208000
CY2014Q3 us-gaap Net Income Loss
NetIncomeLoss
-24786000
CY2014Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-17000
CY2014Q3 us-gaap Operating Expenses
OperatingExpenses
25009000
CY2014Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
8057000
CY2014Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
16952000
CY2015Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
12352000 shares
CY2015Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.39
CY2015Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
100756000 shares
CY2015Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-38872000
CY2015Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-38998000
CY2015Q3 us-gaap Revenues
Revenues
39000
CY2015Q3 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
92000
CY2015Q3 us-gaap Net Income Loss
NetIncomeLoss
-38906000
CY2015Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
34000
CY2015Q3 us-gaap Operating Expenses
OperatingExpenses
39037000
CY2015Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
20308000
CY2015Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
18729000

Files In Submission

Name View Source Status
0001193125-15-368368-index-headers.html Edgar Link pending
0001193125-15-368368-index.html Edgar Link pending
0001193125-15-368368.txt Edgar Link pending
0001193125-15-368368-xbrl.zip Edgar Link pending
acad-20150930.xml Edgar Link completed
acad-20150930.xsd Edgar Link pending
acad-20150930_cal.xml Edgar Link unprocessable
acad-20150930_def.xml Edgar Link unprocessable
acad-20150930_lab.xml Edgar Link unprocessable
acad-20150930_pre.xml Edgar Link unprocessable
d94915d10q.htm Edgar Link pending
d94915dex101.htm Edgar Link pending
d94915dex102.htm Edgar Link pending
d94915dex311.htm Edgar Link pending
d94915dex321.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
g94915image001.jpg Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending